They chose LHRH (pEHWSYGLRPG) as the tumor-targeting moiety, an endogenous peptide agonist targeting LHRH receptors, which is overexpressed in various tumor types [96,97], while the peptide FKKFFRKLL, which they named T2, served as the CPP. This evidence concerns the gene GNRH1 and neoplasm.